Amorfix awarded "Life Science Company of the Year" for moving innovative products into commercialization
Amorfix Life Sciences Ltd. has been selected as the inaugural recipient of the “life science Company of the Year” by The biotechnology Initiative. Amorfix was selected because of its pioneering approaches to innovative diagnostic and therapeutic products for brain-wasting diseases, including Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease), Parkinson’s Disease (PD) and variant Creutzfeldt-Jakob disease (vCJD) for global markets.
“We are honoured to have been selected by The Biotechnology Initiative, and pleased that Amorfix has been identified for its excellence in taking technologies from the bench to the global market. Our vCJD blood test, uniquely designed for living subjects, will lead to immediate protection of the blood supply, and longer term more effective treatments for these baffling diseases,” said Dr. George Adams, President and CEO of Amorfix.
“Ontario is strong when it comes to innovative life sciences companies that are globally competitive. Ontario-based companies like Amorfix are working to quickly move their ideas and world-class research into the global marketplace. That means good jobs for Ontario and hope for people and families suffering from diseases such as Alzheimer’s and Parkinson’s,” said Ontario Minister of Research and Innovation, John Wilkinson. “I commend The Biotechnology Initiative for rewarding research and commercialization excellence - and congratulate Amorfix for winning this year’s award.”
Other news from the department business & finance
